

Latin America Diabetes Devices and Therapeutics Market Investment Opportunities Analysis & Market Size by Diagnosis and Monitoring Devices, Therapeutics,
Combination Drugs, Route of Administration, Type of Diabetes, Distribution
Channels, End User, Competitive Landscape - Q2 2025 Update

Market Report | 2025-03-28 | 210 pages | BioIntel360

# **AVAILABLE LICENSES:**

- Single User Price \$2900.00
- Multi User Price \$3700.00
- Enterprise User Price \$4500.00

# Report description:

According to BioIntel360, diabetes market in Latin America is expected to grow by 8.0% on annual basis to reach US\$6,339.0 million in 2025.

The diabetes market in the region has experienced robust growth during 2020-2024, achieving a CAGR of 8.6%. This upward trajectory is expected to continue, with the market forecast to grow at a CAGR of 6.7% during 2025-2029. By the end of 2029, the diabetes market is projected to expand from its 2024 value of USD 5,870.7 million to approximately USD 8,844.1 million.

Key Trends and Drivers in Latin America's Diabetes Devices and Therapeutics Market

In Latin America, key trends shaping the diabetes devices and therapeutics market include a rising prevalence of diabetes, increased adoption of digital health solutions, and evolving regulatory and reimbursement frameworks. Over the next 2-4 years, these trends are anticipated to intensify, driving expanded access and a more adaptive market landscape for diabetes management.

Examine Rising Diabetes Prevalence and Evolving Patient Needs

- Recent studies from public health agencies in Brazil, Mexico, and Argentina document a rise in diabetes prevalence linked to urbanization, dietary changes, and demographic shifts. Increasing case numbers drive demand for effective monitoring and management solutions across urban centers and remote regions.
- Population structure and lifestyle changes are prompting healthcare systems to enhance screening and early intervention

Scotts International. EU Vat number: PL 6772247784

efforts. Broader healthcare reforms and adjustments in insurance coverage are supporting wider access to diagnostic devices and therapeutics.

- This trend is expected to intensify as public health initiatives expand and healthcare providers invest further in diabetes management technologies. Demand for cost-effective, adaptable devices will likely grow as regional healthcare systems adapt to changing patient needs.

Leverage Digital Health Integration and Remote Monitoring Tools

- Recent publications report increased adoption of digital health solutions in Latin America, with examples from Chile and Colombia, where pilot programs incorporating continuous glucose monitoring (CGM) and telemedicine are underway. These solutions are being tested to improve access and data collection in regions with variable healthcare infrastructure.
- Improvements in internet connectivity and mobile health initiatives are facilitating the use of remote monitoring tools, especially in underserved areas. Investments by public and private sectors in digital infrastructure are creating an environment that supports data-driven management of chronic conditions.
- Digital integration is expected to expand over the coming years, enhancing real-time disease management and personalized care. The trend will likely intensify as regional governments and insurers support digital health strategies to improve clinical outcomes.

Reform Regulatory Frameworks and Expand Reimbursement Policies

- Several Latin American countries have updated their regulatory frameworks for medical devices, as seen in recent publications from Mexico and Argentina, to provide clearer pathways for market entry. These changes coincide with revised reimbursement models that aim to improve patient access to new diabetes therapies.
- The need to control long-term healthcare costs and improve patient outcomes drives regulatory reforms and enhanced insurance coverage. Collaboration between government agencies, insurers, and industry stakeholders is streamlining approval processes and fostering market transparency.
- Regulatory clarity and improved reimbursement models are expected to support steady market expansion, encouraging local and multinational players to invest in Latin America. This trend will likely intensify, creating a more structured and accessible market environment for diabetes devices and therapeutics.

Competitive Landscape in Latin America's Diabetes Devices and Therapeutics Market

The competitive landscape in Latin America is defined by the interplay of longstanding multinational companies and emerging local manufacturers, with a trend toward strategic collaborations and consolidation. Over the next 2-4 years, competitive dynamics are expected to intensify and realign as players adapt to evolving regulatory frameworks and invest in digital health technologies.

# **Assess Current Market Dynamics**

- The market combines established multinational companies and emerging local manufacturers addressing regional clinical and cost considerations. Recent industry reports indicate that economic disparities and varied regulatory environments influence market segmentation and product offerings.

Key Players and Emerging Entrants

- Global companies maintain a strong presence through sustained R&D investments and localized distribution strategies.
- Emerging Brazil, Mexico, and Argentina manufacturers are developing devices tailored to local healthcare practices and budget constraints. These new entrants focus on cost-effective solutions and gradually increase their market share.

Monitor Strategic Collaborations and Consolidation Trends

- Recent transactions highlight collaborations between device manufacturers and local healthcare providers to improve distribution networks and service integration. Industry publications note an uptick in mergers and acquisitions as larger players

Scotts International, EU Vat number: PL 6772247784

look to consolidate regional expertise and expand product portfolios.

- The competitive landscape is expected to consolidate further, with strategic partnerships and acquisitions likely to shape market evolution. Firms that align with local regulatory requirements and invest in digital and remote monitoring technologies are anticipated to secure competitive advantages.

This report provides a detailed data-centric analysis of the diabetes industry in Latin America, covering market opportunities and analysis across a range of diagnosis and monitoring devices, therapeutics, domains. With over 50+ KPIs at the country level, this report provides a comprehensive understanding of diabetes market dynamics, market size and forecast, and market share statistics.

BioIntel360's research methodology is based on industry best practices. Its unbiased analysis leverages a proprietary analytics platform to offer a detailed view of emerging business and investment market opportunities.

This title from BioIntel360 is a bundled offering, combining the following 3 reports, covering 120 tables and 162 figures:

- 1. Latin America Diabetes Devices and Therapeutics Market Opportunity and Future Growth Dynamics (Databook)
- 2. Brazil Diabetes Devices and Therapeutics Market Opportunity and Future Growth Dynamics (Databook)
- 3. Mexico Diabetes Devices and Therapeutics Market Opportunity and Future Growth Dynamics (Databook)

## **Table of Contents:**

This title from BioIntel360 is a bundled offering, combining the following 3 regional and country reports, covering 120 tables and 162 figures:

Regional Report - Latin America Diabetes Devices and Therapeutics Market Opportunity and Future Growth Dynamics (Databook)
Country Report 1 - Brazil Diabetes Devices and Therapeutics Market Opportunity and Future Growth Dynamics (Databook)
Country Report 2 - Mexico Diabetes Devices and Therapeutics Market Opportunity and Future Growth Dynamics (Databook)

All global, regional, and country reports mentioned above will have the following tables of contents:

- 1 About this Report
- 1.1 Research Methodology
- 1.2 Disclaimer
- 2 Diabetes Devices and Therapeutics Market Size and Forecast, 2020-2029
- 3 Diabetes Devices and Therapeutics Market Share by Category, 2020-2029
- 3.1 Diabetes Devices and Therapeutics Market Size by Diagnosis and Monitoring Devices, 2020-2029
- 3.2 Diabetes Devices and Therapeutics Market Size by Therapeutics, 2020-2029
- 4 Diabetes Devices and Therapeutics Market Share by Diagnosis and Monitoring Devices, 2020-2029
- 4.1 Diabetes Devices and Therapeutics Market Size by Blood Glucose Monitoring Devices, 2020-2029
- 4.2 Diabetes Devices and Therapeutics Market Size by Insulin Delivery Devices, 2020-2029
- 4.3 Diabetes Devices and Therapeutics Market Size by Diabetes Management and Mobile Applications, 2020-2029
- 4.4 Diabetes Devices and Therapeutics Market Size by Artificial Pancreas Devices, 2020-2029
- 5 Diabetes Devices and Therapeutics Market Share by Blood Glucose Monitoring Devices, 2020-2029
- 5.1 Diabetes Devices and Therapeutics Market Size by Self-Monitoring Blood Glucose Devices, 2020-2029

Scotts International, EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

- 5.2 Diabetes Devices and Therapeutics Market Size by Continuous Blood Glucose Monitoring Devices, 2020-2029
- 5.3 Diabetes Devices and Therapeutics Market Size by Test Strips, 2020-2029
- 5.4 Diabetes Devices and Therapeutics Market Size by Lancets, 2020-2029
- 6 Diabetes Devices and Therapeutics Market Share by Insulin Delivery Devices, 2020-2029
- 6.1 Diabetes Devices and Therapeutics Market Size by Insulin Pumps, 2020-2029
- 6.2 Diabetes Devices and Therapeutics Market Size by Insulin Pens, 2020-2029
- 6.3 Diabetes Devices and Therapeutics Market Size by Insulin Syringes, 2020-2029
- 7 Diabetes Devices and Therapeutics Market Share by Therapeutics, 2020-2029
- 7.1 Diabetes Devices and Therapeutics Market Size by Oral Anti-Diabetic Drugs, 2020-2029
- 7.2 Diabetes Devices and Therapeutics Market Size by Insulin, 2020-2029
- 7.3 Diabetes Devices and Therapeutics Market Size by Non-Insulin Injectable Drugs, 2020-2029
- 7.4 Diabetes Devices and Therapeutics Market Size by Combination Drugs, 2020-2029
- 8 Diabetes Devices and Therapeutics Market Share by Oral Anti-Diabetic Drugs, 2020-2029
- 8.1 Diabetes Devices and Therapeutics Market Size by Alpha-Glucosidase Inhibitors, 2020-2029
- 8.2 Diabetes Devices and Therapeutics Market Size by DPP-4 Inhibitors, 2020-2029
- 8.3 Diabetes Devices and Therapeutics Market Size by SGLT-2 Inhibitors, 2020-2029
- 9 Diabetes Devices and Therapeutics Market Share by Insulin, 2020-2029
- 9.1 Diabetes Devices and Therapeutics Market Size by Basal or Long-Acting, 2020-2029
- 9.2 Diabetes Devices and Therapeutics Market Size by Bolus or Fast-Acting, 2020-2029
- 9.3 Diabetes Devices and Therapeutics Market Size by Traditional Human Insulin Drugs, 2020-2029
- 9.4 Diabetes Devices and Therapeutics Market Size by Insulin Biosimilars, 2020-2029
- 10 Diabetes Devices and Therapeutics Market Share by Non-Insulin Injectable Drugs, 2020-2029
- 10.1 Diabetes Devices and Therapeutics Market Size by GLP-1 Receptor Agonists, 2020-2029
- 10.2 Diabetes Devices and Therapeutics Market Size by Amylin Analogue, 2020-2029
- 11 Diabetes Devices and Therapeutics Market Share by Combination Drugs, 2020-2029
- 11.1 Diabetes Devices and Therapeutics Market Size by Combination Insulin, 2020-2029
- 11.2 Diabetes Devices and Therapeutics Market Size by Oral Combination, 2020-2029
- 12 Diabetes Devices and Therapeutics Market Share by Route of Administration, 2020-2029
- 12.1 Diabetes Devices and Therapeutics Market Size by Subcutaneous, 2020-2029
- 12.2 Diabetes Devices and Therapeutics Market Size by Intravenous, 2020-2029
- 12.3 Diabetes Devices and Therapeutics Market Size by Others, 2020-2029
- 13 Diabetes Devices and Therapeutics Market Share by Type of Diabetes, 2020-2029
- 13.1 Diabetes Devices and Therapeutics Market Size by Type 2 Diabetes, 2020-2029
- 13.2 Diabetes Devices and Therapeutics Market Size by Type 1 Diabetes, 2020-2029
- 14 Diabetes Devices and Therapeutics Market Share by Distribution Channels, 2020-2029
- 14.1 Diabetes Devices and Therapeutics Market Size by Online Pharmacies, 2020-2029
- 14.2 Diabetes Devices and Therapeutics Market Size by Hospital Pharmacies, 2020-2029
- 14.3 Diabetes Devices and Therapeutics Market Size by Retail Pharmacies, 2020-2029

Scotts International, EU Vat number: PL 6772247784

- 15 Diabetes Devices and Therapeutics Market Share by End User, 2020-2029
- 15.1 Diabetes Devices and Therapeutics Market Size by Hospitals, 2020-2029
- 15.2 Diabetes Devices and Therapeutics Market Size by Diabetes Clinics, 2020-2029
- 15.3 Diabetes Devices and Therapeutics Market Size by Homecare, 2020-2029
- 16 Further Reading
- 16.1 About BioIntel360
- 16.2 Related Research
- 16.3 Consulting



To place an Order with Scotts International:

☐ - Print this form

# Latin America Diabetes Devices and Therapeutics Market Investment Opportunities Analysis & Market Size by Diagnosis and Monitoring Devices, Therapeutics, Combination Drugs, Route of Administration, Type of Diabetes, Distribution Channels, End User, Competitive Landscape - Q2 2025 Update

Market Report | 2025-03-28 | 210 pages | BioIntel360

☐ - Complete the re	elevant blank fields and sign			
<ul><li>Send as a scan</li></ul>	ned email to support@scotts-intern	ational.com		
ORDER FORM:				
Select license	License			Price
	Single User Price			\$2900.00
	Multi User Price			\$3700.00
	Enterprise User Price			\$4500.00
			VAT	
			Tota	
	ant license option. For any questions pl			
** VAT will be added a	at 23% for Polish based companies, indi	viduals and EU based of	companies who are unable to provide a	valid EU Vat Numbe
Email*		Phone*		
Elliali		riione		
First Name*		Last Name*		
Job title*				
Company Name*		EU Vat / Tax ID /	/ NIP number*	
Address*		City*		
Zip Code*		Country*		

Scotts International. EU Vat number: PL 6772247784

Date	2025-06-24
Signature	